This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Sar 56 kDa
Drug Names(s): HEV Vaccine
Description: HEV was first isolated and cloned by Genelabs scientists working in conjunction with researchers from the U.S. Centers for Disease Control and Prevention. U.S. patents that broadly claim HEV genomes, DNA fragments and their encoded proteins have issued to Genelabs.
Deal Structure: Genelabs has granted an exclusive worldwide license to GlaxoSmithKline (GSK) for vaccine applications under Genelabs' HEV patent portfolio. The agreement provides Genelabs with milestone payments when GlaxoSmithKline reaches certain development goals and Genelabs would receive royalties should HEV vaccine products developed under this license be sold.
Novavax in collaboration with the National Institute of Allergy and Infectious Disease, Walter Reed Army Institute for Research, and GSK helped develop the vaccine. Novavax will share royalties with the NIH.
In October 2008, GlaxoSmithKline and Genelabs Technologies announced that they entered into a definitive agreement pursuant to which GSK will acquire Genelabs for approximately $57 million (35 million) through a tender offer of $1.30 per share in cash. The acquisition was completed in January 2009.
Partners: Novavax, Inc.
Sar 56 kDa News
Pink Sheet US Senate Approves BioShield Funding
Pink Sheet Aronex Nyotran
Additional information available to subscribers only: